Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Daniel Benz

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|February 3, 2007
Toxicological and clinical computational analysis and the US FDA/CDERR Daniel Benz
Current Opinion in Drug Discovery & Development|February 1, 2006
Landscape of current toxicity databases and database standardsChihae Yang, R Daniel Benz, Mitchell A Cheeseman
Regulatory Toxicology and Pharmacology : RTP|November 19, 2003
Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indicesJoseph F Contrera, Edwin J Matthews, R Daniel Benz
Regulatory Toxicology and Pharmacology : RTP|January 9, 2007
A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR databaseEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2004
Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily doseJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Regulatory Toxicology and Pharmacology : RTP|October 26, 2005
In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR softwareJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Toxicology Mechanisms and Methods|December 22, 2009
In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property DescriptorsJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Advanced Drug Delivery Reviews|January 19, 2007
Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated productsNaomi L Kruhlak, Joseph F Contrera, R Daniel Benz, et al.
Regulatory Toxicology and Pharmacology : RTP|August 21, 2007
Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR modelsJoseph F Contrera, Naomi L Kruhlak, Edwin J Matthews, et al.
Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial dataEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Expert Opinion on Drug Metabolism & Toxicology|February 3, 2007
Toxicological and clinical computational analysis and the US FDA/CDERR Daniel Benz
Current Opinion in Drug Discovery & Development|February 1, 2006
Landscape of current toxicity databases and database standardsChihae Yang, R Daniel Benz, Mitchell A Cheeseman
Regulatory Toxicology and Pharmacology : RTP|November 19, 2003
Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indicesJoseph F Contrera, Edwin J Matthews, R Daniel Benz
Regulatory Toxicology and Pharmacology : RTP|January 9, 2007
A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR databaseEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2004
Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily doseJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Regulatory Toxicology and Pharmacology : RTP|October 26, 2005
In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR softwareJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Toxicology Mechanisms and Methods|December 22, 2009
In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property DescriptorsJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Advanced Drug Delivery Reviews|January 19, 2007
Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated productsNaomi L Kruhlak, Joseph F Contrera, R Daniel Benz, et al.
Regulatory Toxicology and Pharmacology : RTP|August 21, 2007
Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR modelsJoseph F Contrera, Naomi L Kruhlak, Edwin J Matthews, et al.
Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial dataEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Pageof 3